NCI-H526 [H526] (ATCC® CRL-5811)

Organism: Homo sapiens, human  /  Cell Type: epithelial  /  Disease: stage E,carcinoma; variant small cell lung cancer

Permits and Restrictions

View Restrictions

Organism Homo sapiens, human
Cell Type epithelial
Product Format frozen
Morphology epithelial
Culture Properties round clusters in suspension
Biosafety Level 1
Disease stage E,carcinoma; variant small cell lung cancer
Age 55 years adult
Gender male
Ethnicity Caucasian
Storage Conditions liquid nitrogen vapor phase
Derivation
This line was derived by A.F. Gazdar, H.K. Oie, J.D. Minna and associates from a bone marrow metastasis taken from a patient prior to therapy.
Clinical Data
55 years adult
Caucasian
male
Receptor Expression
insulin-like growth factor II (IGF II); bombesin
Oncogene myc +; myb +; fes +; fms +; raf +; ras +
Tumorigenic Yes
Effects
Yes, the cells produce tumors in athymic nude mice
Comments
NCI-H526 expresses elevated levels of 2 biochemical markers of SCLC: neuron specific enolase and the brain isoenzyme of creatine kinase.
They do not express L-dopa carboxylase or bombesin-like immunoreactivity.
These cells express the c-kit gene as well as the N-myc gene, but not c-myc or L-myc.
N-myc is amplified and p75 c-myb expression was observed.
NCI-H526 also expresses the proto-oncogenes N-ras, Ki-ras, Ha-ras, and c-raf1.
Only trace amounts of the retinoblastoma susceptibility gene, RB mRNA were detected.
RB protein was not detected.
The cells express easily detectable levels of p53 mRNA compared to levels found in normal lung.
Abnormally sized mRNA was present.
The line has a reported colony-forming efficiency of 4.2% in soft agarose.
Complete Growth Medium The base medium for this cell line is ATCC-formulated RPMI-1640 Medium, Catalog No. 30-2001. To make the complete growth medium, add the following components to the base medium: fetal bovine serum to a final concentration of 10%.
Subculturing

Cultures can be maintained by addition of fresh medium or replacement of medium. Alternatively, cultures can be established by centrifugation of the suspension with subsequent resuspension in fresh medium. Add medium as the cell density increases.

Medium Renewal: Every 2 to 3 days

 

Cryopreservation
Culture medium, 95%; DMSO, 5%
Culture Conditions
Temperature: 37°C
STR Profile
Amelogenin: X,Y
CSF1PO: 11
D13S317: 13
D16S539: 9
D5S818: 11
D7S820: 9,12
THO1: 6,8
TPOX: 8,11
vWA: 16,17
Population Doubling Time 36 hrs
Name of Depositor AF Gazdar, JD Minna
References

Takahashi T, et al. p53: A frequent target for genetic abnormalities in lung cancer. Science 246: 491-494, 1989. PubMed: 2554494

Bepler G, et al. Expression of p64c-myc and neuroendocrine properties define three subclasses of small cell lung cancer. Oncogene 4: 45-50, 1989. PubMed: 2536917

Schardt C, et al. Characterization of insulin-like growth factor II receptors in human small cell lung cancer cell lines. Exp. Cell Res. 204: 22-29, 1993. PubMed: 8380141

Lai SL, et al. Molecular genetic characterization of neuroendocrine lung cancer cell lines. Anticancer Res. 15: 225-232, 1995. PubMed: 7762988

Carney DN, et al. Establishment and identification of small cell lung cancer cell lines having classic and variant features. Cancer Res. 45: 2913-2923, 1985. PubMed: 2985257

Kiefer PE, et al. Amplification and expression of protooncogenes in human small cell lung cancer cell lines. Cancer Res. 47: 6236-6242, 1987. PubMed: 2824028

Hensel CH, et al. Altered structure and expression of the human retinoblastoma susceptibility gene in small cell lung cancer. Cancer Res. 50: 3067-3072, 1990. PubMed: 2159370

Ohsaki Y, et al. Human small cell lung cancer cell lines express functional atrial natriuretic peptide receptors. Cancer Res. 53: 3165-3171, 1993. PubMed: 8391389

Plummer H, et al. c-myc expression correlates with suppression of c-kit protooncogene expression in small cell lung cancer cell lines. Cancer Res. 53: 4337-4342, 1993. PubMed: 7689933

Verbeeck MA, et al. Expression of the vasopressin and gastrin-releasing peptide genes in small cell lung carcinoma cell lines. Pathobiology 60: 136-142, 1992. PubMed: 1320893

Johnson BE, et al. Retention of chromosome 3 in extrapulmonary small cell cancer shown by molecular and cytogenetic studies. J. Natl. Cancer Inst. 81: 1223-1228, 1989. PubMed: 2569043

Bepler G, et al. Substance P analogues function as bombesin receptor antagonists and inhibit small cell lung cancer clonal growth. Peptides 9: 1367-1372, 1988. PubMed: 2470067

NCI-Navy Medical Oncology Branch Cell Line Supplement. J. Cell. Biochem. suppl. 24: 1996.

Lung Cancer 4: 155-161, 1988.

Basic Documentation
Restrictions

The line is available with the following restrictions: 1. This cell line was deposited at the ATCC by Dr. A. Gazdar and Dr. J. Minna and is provided for research purposes only. Neither the cell line nor products derived from it may be sold or used for commercial purposes. Nor can the cells be distributed to third parties for purposes of sale, or producing for sale, cells or their products. The cells are provided as service to the research community. They are provided without warranty of merchantability or fitness for a particular purpose or any other warranty, expressed or implied. 2. Any proposed commercial use of the these cells, or their products must first be negotiated with the University of Texas Southwestern Medical Center at Dallas, 5323 Harry Hines Blvd., Dallas, Texas 75235. Telephone (214) 699-8056, FAX (214) 688-7233.

References

Takahashi T, et al. p53: A frequent target for genetic abnormalities in lung cancer. Science 246: 491-494, 1989. PubMed: 2554494

Bepler G, et al. Expression of p64c-myc and neuroendocrine properties define three subclasses of small cell lung cancer. Oncogene 4: 45-50, 1989. PubMed: 2536917

Schardt C, et al. Characterization of insulin-like growth factor II receptors in human small cell lung cancer cell lines. Exp. Cell Res. 204: 22-29, 1993. PubMed: 8380141

Lai SL, et al. Molecular genetic characterization of neuroendocrine lung cancer cell lines. Anticancer Res. 15: 225-232, 1995. PubMed: 7762988

Carney DN, et al. Establishment and identification of small cell lung cancer cell lines having classic and variant features. Cancer Res. 45: 2913-2923, 1985. PubMed: 2985257

Kiefer PE, et al. Amplification and expression of protooncogenes in human small cell lung cancer cell lines. Cancer Res. 47: 6236-6242, 1987. PubMed: 2824028

Hensel CH, et al. Altered structure and expression of the human retinoblastoma susceptibility gene in small cell lung cancer. Cancer Res. 50: 3067-3072, 1990. PubMed: 2159370

Ohsaki Y, et al. Human small cell lung cancer cell lines express functional atrial natriuretic peptide receptors. Cancer Res. 53: 3165-3171, 1993. PubMed: 8391389

Plummer H, et al. c-myc expression correlates with suppression of c-kit protooncogene expression in small cell lung cancer cell lines. Cancer Res. 53: 4337-4342, 1993. PubMed: 7689933

Verbeeck MA, et al. Expression of the vasopressin and gastrin-releasing peptide genes in small cell lung carcinoma cell lines. Pathobiology 60: 136-142, 1992. PubMed: 1320893

Johnson BE, et al. Retention of chromosome 3 in extrapulmonary small cell cancer shown by molecular and cytogenetic studies. J. Natl. Cancer Inst. 81: 1223-1228, 1989. PubMed: 2569043

Bepler G, et al. Substance P analogues function as bombesin receptor antagonists and inhibit small cell lung cancer clonal growth. Peptides 9: 1367-1372, 1988. PubMed: 2470067

NCI-Navy Medical Oncology Branch Cell Line Supplement. J. Cell. Biochem. suppl. 24: 1996.

Lung Cancer 4: 155-161, 1988.